Relevance of Platinum-free Interval and BRCA Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for gBRCA Advanced Breast Cancer (BROCADE3 Crossover)

PURPOSE: Safety, efficacy, and exploratory biomarker analyses were evaluated in patients with advanced HER2-negative germline breast cancer susceptibility gene (gBRCA)-associated breast cancer enrolled in the BROCADE3 trial who received crossover veliparib monotherapy after disease progression on pl...

Descripción completa

Detalles Bibliográficos
Autores principales: Puhalla, Shannon L., Diéras, Véronique, Arun, Banu K., Kaufman, Bella, Wildiers, Hans, Han, Hyo S., Ayoub, Jean-Pierre, Stearns, Vered, Yuan, Yuan, Helsten, Teresa, Riley-Gillis, Bridget, Murphy, Erin, Kundu, Madan G., Wu, Meijing, Maag, David, Ratajczak, Christine K., Ramathal, Cyril Y., Friedlander, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401555/
https://www.ncbi.nlm.nih.gov/pubmed/34131001
http://dx.doi.org/10.1158/1078-0432.CCR-21-0748

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401555/
https://www.ncbi.nlm.nih.gov/pubmed/34131001
http://dx.doi.org/10.1158/1078-0432.CCR-21-0748

Ejemplares similares